Trial Profile
Safety and efficacy of sitagliptin plus granulocyte-colony stimulating factor [lenograstim] in patients suffering from acute myocardial infarction
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Lenograstim (Primary) ; Sitagliptin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms SITAGRAMI
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 07 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov record.